Podcasts

Bios:

Dr. Eric Donnenfeld
Dr. Eric Donnenfeld is an internationally recognized surgeon and expert in refractive, cornea and cataract surgery in the United States.  He has won numerous awards, including being named Newsweek’s best ophthalmologist in America in both 2022 and 2021. He is currently a National Medical Director of TLC Laser Eye Centers and Surgical Director of the Lions Eye Bank for Long Island.

Dr. John Hovanesian
Dr. John Hovanesian is a cataract, corneal, and laser eye surgeon.  He was recognized by Newsweek as one of the top 35 eye surgeons in the United States and by The Ophthalmologist as one of the world’s 100 most influential people in eye care.  He is the owner of Harvard Eye Associates in California.

Summary:

In this episode of ‘Peer2Peer: The Podcast’, Dr. Eric Donnenfeld and Dr. John Hovanesian discuss a recent clinical study evaluating clinical efficacy and patient preference for a dropless treatment regimen following cataract surgery, as well as other innovative dropless solutions.

Key Takeaways:

• Challenges with Conventional Drop Usage: Donnenfeld discusses the 5 C’s relating to drug delivery and topical drops, highlighting issues surrounding compliance, corneal toxicity, comfort, cost, and cosmesis.
• The Importance of a Non-Steroidal: Donnenfeld and Dr. Hovanesian question whether steroid, non-steroidal, and antibiotic drugs are really all necessary and agree that the non-steroidal is the most important part of a post-operative regimen for cataract surgery.
• Linchpin to Cataract Surgery: Donnenfeld believes that non-steroidals are the linchpin to cataract surgery, preventing inflammation and preventing CME, as well as providing comfort to the patient because they reduce inflammation and pain post-surgery.
• A Powerful Combination: OMIDRIA is a combination drug that consists of Phenylephrine 1% and Ketorolac 0.3%. Dr. Donnenfeld and Dr. Hovanesian highlight its ability to maintain mydriasis, reduce complications, decrease surgical time, and improve patient comfort.
• Study Findings on a Dropless Regimen: Donnenfeld and Dr. Hovanesian share results from their study comparing a traditional three-drop regimen versus a dropless regimen. There was no difference in clinical outcomes, but 95% of patients said when given the choice, they absolutely preferred the dropless regimen.
• The Future of Drops: Dr. Donnenfeld and Dr. Hovanesian conclude by acknowledging that relying on three different drops for surgery is not necessary, and that using sustained drug delivery methods such as OMIDRIA can make surgery safer and improve patient outcomes.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Follow Dr Eric Donnenfeld on social:
Dr Eric Donnenfeld | LinkedIn

Follow Dr John Hovanesian on social:
Dr John Hovanesian | LinkedIn

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/

OMIDRIA HCP Portal:
https://www.omidriahcp.com/

Dr. Donnenfeld and Dr. Hovanesian’s study comparing a traditional three- drop regimen with a dropless treatment regimen including OMIDRIA
here

US-OM-2300050 01/24

Bios:

Dr Inder Paul Singh (host)

Dr Inder Paul Singh president of The Eye Centres of Racine & Kenosha Ltd. in Wisconsin. His clinical research has been published and presented at various national meetings and universities around the world. Dr. Singh was also named America’s Best Eye Doctor in 2021 by Newsweek.

Dr Arjan Hura (guest)

Dr Arjan Hura is a refractive cataract and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, California.

Dr Karolinne Rocha (guest)

Dr Karolinne Rocha is assistant Professor of Ophthalmology at MUSC in Charleston, South Carolina specializing in cataract, cornea, and refractive surgery.

Summary:

Dr Paul Singh is joined by Dr Arjan Hura and Dr Karolinne Rocha at AECOS 2023 in Deer Valley to discuss why they are adopting OMIDRIA. They touch a multitude of topics including the importance of maintaining pupil stability, accessibility to the medication, patient selection, and patient experience.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon’s independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases.

Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300041 11/23

Key Takeaways:

• An optimized combination: OMIDRIA combines phenylephrine and ketorolac to calm inflammation and maintain pupil size during surgery.
• A game changer: Dr. Karolinne Rocha explains that OMIDRIA has been a game changer in her practice and specifically for patients with floppy iris syndrome and for femtosecond laser cases.
• Rapid results: When Dr. Arjan Hura started using OMIDRIA, he noticed less anterior chamber inflammation and less postoperative edema. Patients were seeing and reading better after just one day post-op.
• Building confidence: Paul Singh highlights the fact that he is more confident during surgery with OMIDRIA. He uses less pupil expansion devices and has improved overall efficiency while decreasing surgical times.
• Decreasing the drop burden: Hura and Dr. Singh agree that having OMIDRIA on board decreases post-op inflammation and has reduced patients’ drop regimen after surgery.
• Improving patient experience: As Dr. Hura explains, moving towards a dropless future can increase overall patient experience by reducing stress related to following complicated drop regimens and reducing callbacks and time at post-op appointments..
• Accessibility for (almost) all: OMIDRIA is easily accessible for the majority of patients and is now covered separately through 2028. Dr. Singh, Dr. Hura, and Dr. Rocha all note that they use it on almost every patient.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Follow Dr Inder Paul Singh on social:
Dr Inder Paul Singh | LinkedIn

Follow Dr Arjan Hura on social:
Dr Arjan Hura | LinkedIn

Follow Dr Karolinne Rocha on social:
Dr Karolinne Rocha | LinkedIn

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/

OMIDRIA HCP Portal:
https://www.omidriahcp.com/

US-OM-2300041 11/23

Bios:

Dr Arjan Hura (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

William Wiley (guest)

William Wiley is a Board-Certified Ophthalmologist who has pioneered many eye procedures in the Northeast Ohio area. Dr. Wiley is the Medical Director of the Cleveland Eye Clinic. Dr. Wiley was one of the first in the area to offer his patients all-laser LASIK as well as laser-assisted refractive cataract surgery.

Summary:

In the last episode of ‘Peer2Peer: The Podcast’, OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3% series, the host, Dr Arjan Hura, shares a conversation with Dr. William Wiley from the Cleveland Eye Clinic about implementing OMIDRIA into clinical practice. The discussion dives into their early initial experiences with OMIDRIA through to today where it is employed in all of their cataract procedures.

Key Takeaways:

• OMIDRIA has a noticeable impact when introduced as standard practice: Even as a surgeon in residency, Dr Hura’s experience was that the difference was dramatic: less complications after cataract surgeries, far less need for iris expansion devices, reduced pain following surgeries, and visually healthier eyes with less cell and improved visual acuity.
• OMIDRIA provides constant infusion of dilation throughout a surgery and makes the lives of both patients and surgeons easier: Dr Wiley, though initially resistant to adopting OMIDRIA, quickly recognised the benefits including reduction of postoperative inflammation and pain.
• OMIDRIA may reduce the need for risky painkillers: Dr Wiley has nearly eliminated the need for opioids such as fentanyl in postsurgical care by employing OMIDRIA during surgery.
• OMIDRIA can lessen the need for post-operative drops: Dr Wiley shares that OMIDRIA, containing an intraoperative NSAID, has allowed his clinic to simplify their post-operative regimen to 1 drop per day.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

US-OM-2300033 07/23

Bios:

Dr Arjan Hura (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

Dr Denise Visco (guest)

Dr Denise Visco is an ophthalmologist in York, Pennsylvania and is affiliated with UPMC Memorial. Dr. Visco is a pioneer of surgical advancement being the first female surgeon in the world to perform cataract surgery with the LENSAR Advanced Laser Cataract System. She is also the first in the area to offer all laser LASIK procedures and customized options for cataract surgery.

Dr Steven Silverstein (guest)

Dr. Steven Silverstein is a  board-certified ophthalmologist and fellow of the American College of Surgeons.

Summary:

This episode of ‘Peer2Peer: The Podcast’, focuses on clinical performance and results from studies conducted with OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3%, in cataract surgery. The episode, featuring Dr. Denise Visco and Dr. Steven Silverstein, highlights the potential advantages of OMIDRIA in cataract surgery shown by rigorous clinical trials, including improved patient compliance, reduction in post-operative drops, and reduced reliance on pain medications, without increasing the risk of complications.

Key Takeaways:

• The use of OMIDRIA in cataract surgery reduces the intraoperative need for pain medications²: Dr. Visco’s research, where OMIDRIA replaced steroids in the operating room for some of the patients, showed that CME was three times less likely for patients who had received OMIDRIA. Patients where steroids had been used were also twice as likely to appear for post-op visits for photophobia or rebound iritis, with no adverse effects from OMIDRIA. Postoperative NSAIDS could be reduced from 10 to 4 weeks when OMIDRIA was used on the patient with no increase in CME, iritis, pain or photophobia¹.
• With high-risk patients, OMIDRIA has been shown to significantly decrease to all three facets of IFIS: A rigorous, non-funded double-blind study by Dr. Silverstein determined that iris prolapse, billowing and flaccidity were dramatically reduced in severity and excursion when men on Tamsulosin received OMIDRIA in their irrigation solution for their cataract surgery. And as before, there was significantly less need for postoperative medications where OMIDRIA was used³.
• Dropless cataract surgery has a number of benefits: Improved patient compliance; reduced need for additional pain medication; and fewer postoperative complications.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

Referenced Publications:

1. Controlling Postoperative Inflammation and Associated Complications with OMIDRIA
   By Dr. Denise Visco
2. Pain control and the reduction of opioid use associated with intracameral phenylephrine 1.0%-ketorolac 0.3% administered during cataract surgery
   By Dr. Eric Donnenfeld, et al.
3. Effect of phenylephrine 1.0%-ketorolac 0,3% injection on tamsulosin-associated intraoperative floppy-iris syndrome
   By Steven Silverstein, et al.

US-OM-2300030 07/23

Bios:

Dr Arjan Hura (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

Dr Cathleen McCabe (guest)

Dr Cathleen McCabe is a cataract and refractive specialist serving as Chief Medical Officer at Eye Health America™. She is one of the foremost eye surgeons today, specializing in bladeless laser cataract surgery and LASIK at The Eye Associates in Sarasota, Florida.  Dr McCabe was recently honored for being on the Global Top 100 Power list for 2021 and 2022.

Dr Neda Shamie (guest)

Dr Neda Shamie is a cataract, LASIK and corneal surgeon and partner of the Maloney-Shamie Vision Institute in Los Angeles. She previously was the Medical Director of the Doheny Eye Institute in Beverly Hills and is an Adjunct Clinical Professor of Ophthalmology at the USC Keck School of Medicine.

Summary:

In this second episode of ‘Peer2Peer: The Podcast’ focused on OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, host Dr Arjan Hura, discusses the use of OMIDRIA with Dr Cathleen McCabe and Dr Neda Shamie. They highlight the challenges faced by surgeons who suffer from high workloads and how OMIDRIA can help mitigate some of the risks associated with stress in case of complications. Additionally, they explain the benefits of using OMIDRIA with high-risk patients, and the reasons why they often apply it in less complicated cases as well.

Key Takeaways:

• OMIDRIA reduces the risk of surgeries regardless of experience: Dr Shamie, Dr McCabe, and Dr Hura are all highly experienced cataract surgeons and view such surgeries as routine. Nonetheless, their experiences have shown that using OMIDRIA reduces the difficulty of surgical procedures, which is a significant boon when operating several times a day, working under pressure, or performing surgeries that require the usage of additional tools that may multiply risk and can lead to additional inflammation for the patient.
• OMIDRIA’s positive impact is clinically proven: Dr McCabe explains that OMIDRIA’s studies have demonstrated significant CME reduction, with lower rates of rebound iritis, postoperative inflammation, and pain for the patients. This in turn requires far less deployment of risky opioid painkillers such as fentanyl.
• OMIDRIA’s impact is heightened with high-risk patients: Shamie points out that diabetic patients, and others who are prone to inflammation, CME, miotic pupils or floppy irises may have strong benefits from OMIDRIA, as the advantages provided by what Dr McCabe refers to as incremental improvements are higher.
• Surgeons find it easy to work with the company: Shamie explains that if there are questions regarding insurance or reimbursements, Rayner’s representatives are responsive and happy to provide support.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

US-OM-2300031 07/23

Bios:

Dr Arjan Hura  (host)

Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.

Dr Gary Foster (guest)

Dr Gary Foster is a board-certified ophthalmologist, specializing in cataract and laser eye surgery in Colorado and Wyoming.

Dr Rebecca Metzinger (guest)

Dr Rebecca Metzingeris chief of ophthalmology at the Southeast Louisiana Veterans Health Care System. Dr. Metzinger’s research interests include prevention of corneal transplant rejection, facial nerve regeneration, and immunosuppressants.

Dr Denise Visco (guest)

Dr Denise Visco is an ophthalmologist in York, Pennsylvania and is affiliated with UPMC Memorial. Dr. Visco is a pioneer of surgical advancement being the first female surgeon in the world to perform cataract surgery with the LENSAR Advanced Laser Cataract System. She is also the first in the area to offer all laser LASIK procedures and customized options for cataract surgery.

Dr Neda Nikpoor (guest)

Dr Neda Nikpoor is a fellowship-trained and board-certified ophthalmologist performing cataract, cornea, and LASIK surgery at Aloha Laser Vision. As a highly acclaimed ophthalmologist, Dr. Nikpoor has made a positive global impact during her career.

Dr Inder Paul Singh (guest)

Dr Inder Paul Singh is an ophthalmologist in Racine, Wisconsin and is President of The Eye Centers of Racine & Kenosha, Ltd. He has a strong passion for new technology. He was the first surgeon in Wisconsin to perform many of the minimally invasive glaucoma surgeries (MIGS), such as the iStent, Cypass, Hydrus, and Kahook Dual Blade goniotomy. In 2021, Newsweek named Dr. Singh America’s Best Eye Doctor for quality of care, continuity of care, and the quality of the technology used in his practice.

Dr Kendall Donaldson (guest)

Dr Kendall Donaldson is a cornea specialist at the Bascom Palmer Eye Institute, whose primary research interests are in the areas of advancement in cataract surgery, and in particular, laser-assisted cataract surgery, and severe ocular surface disease. She performs various types of corneal transplantation procedures, laser vision correction procedures, ocular surface reconstruction, and cataract surgery.

Dr Keith Walter (guest)

Dr Keith Walter is a Professor of Ophthalmology, Director of the Cornea Fellowship and also a LASIK eye surgeon with Wake Forest Baptist Health in Winston-Salem, NC.

Mitch Jackson (guest)

Mitch Jackson is a board-certified ophthalmologist specializing in cataract and refractive surgery. He is the Founder and Medical Director of Jackson Eye and is also a clinical associate at the University of Chicago Hospitals.

Summary:

This episode of ‘Peer2Peer: The Podcast’ is the first from a series of four episodes dedicated to OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. Dr Arjan Hura, together with top surgeons Gary Foster, Rebecca Metzinger, Denise Visco, Neda Nikpoor, Inder Paul Singh, Kendall Donaldson, Keith Walter, Mitch Jackson share their thoughts and experience on the use of OMIDRIA in cataract surgery. They highlight the benefits of incorporating OMIDRIA, including an improved surgeon, practice, and patient perioperative experience.

Key Takeaways:

• Incorporating OMIDRIA can enhance safety and predictability in the surgical practice.
• Integrating OMIDRIA into cataract surgery training programs may ease the procedure for new surgeons, reduce complications, and enhance surgical outcomes. The experiences shared by surgeons highlight the efficacy, safety, and positive impact of OMIDRIA in cataract surgery.
• Surgeons recommend contacting OMIDRIA representatives when starting to use the product, as Field Reimbursement Managers can assist with billing and reimbursement questions and Sales Representatives can help provide guidance on integration into the surgical workflow. Many surgeons have been pleased with the new enhanced OMIDRIAssure Patient Access Program. 

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

Additional Resources:

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/
OMIDRIA HCP Portal:
https://www.omidriahcp.com/

US-OM-2300030 07/23